8-K

                                  UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549

                                    FORM 8-K


                                 CURRENT REPORT

                         Pursuant to Section 13 or 15(d)
                     of the Securities Exchange Act of 1934

         Date of Report (Date of earliest event reported): July 15, 2004



                           Integrated BioPharma, Inc.
                           --------------------------
             (Exact name of registrant as specified in its charter)


           Delaware                      000-28876               22-2407475
           --------                      ---------               ----------
(State or other jurisdiction of (Commission File Number) (IRS Employer
 incorporation or organization) Identification No.)


           225 Long Avenue
         Hillside, New Jersey                             07205
         --------------------                             -----
(Address of principal executive offices)                (Zip Code)


       Registrant's telephone number, including area code: (973) 926-0816



                                 Not Applicable
          (Former name or former address, if changed since last report)






Item 5.       Other Events and Regulation FD Disclosure.

         On July 14, 2004, Integrated BioPharma, Inc., a Delaware corporation
(the "Company"), issued a press release stating that there is a fraudulent press
release posted on the INB section of the Yahoo Finance message board. The
statement is false and was not issued by or on behalf of INB. The press release
is attached as an exhibit to this Report.


Item 7.      Financial Statements and Exhibits

(c) Exhibits.

Exhibit No.  Description
99.1         Press Release issued by Integrated BioPharma, Inc. on July 14, 2004






                                   SIGNATURES

         Pursuant to the requirements of the Securities Exchange Act of 1934,
the Registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.


Date:  July 15, 2004              INTEGRATED BIOPHARMA, INC.


                                  By: /s/ Eric Friedman
                                  Eric Friedman
                                  Vice President and Chief Financial Officer







                                  Exhibit Index

Exhibit No.  Description
99.1         Press Release issued by Integrated BioPharma, Inc. on July 14, 2004

EX-99

                                                                    EXHIBIT 99.1

FOR IMMEDIATE RELEASE                                Contact: Eric Friedman
July 14, 2004                                        Investor Relations
                                                     (973)-926-0816

            Integrated BioPharma Responds to Fraudulent Press Release

Hillside, N.J., July 14, 2004--Integrated BioPharma, Inc. (Amex: INB) recently
learned that a fraudulent press release, purporting to be issued by INB, was
posted on the INB section of the Yahoo Finance message board. The fabricated
release stated that the Company had determined to halt trading of its common
stock on the American Stock Exchange. That statement is false and was not issued
by or on behalf of INB. In fact, the stock continues to be actively traded on
the American Stock Exchange and the Company has no intention to halt trading on
the Amex. Yahoo has since removed the message from its site following a demand
from the Company and its counsel.

The Company wishes to alert investors that Web site postings such as this
apparently are a part of recent activities to illicitly manipulate the Company's
stock price, and that information contained in such message boards should
therefore not be relied on by investors in making their investment decisions.
The Company, together with its counsel, is investigating these activities and
has notified the American Stock Exchange and the Securities and Exchange
Commission. The Company has demanded information to identify the source of the
false posting and will pursue obtaining such information and take appropriate
action.

INB serves the pharmaceutical, biotech and nutraceutical industries. Through
several wholly owned subsidiaries, INB develops, manufactures and distributes
more than 130 products worldwide. Its subsidiary, Paxis Pharmaceuticals, Inc.,
develops and operates a state-of-the-art GMP facility for the production and
sale of paclitaxel and related drugs. Through its biotech subsidiary, NuCycle
Therapy, Inc., INB is developing human therapeutics and preventive cancer
compounds in transgenic plants. Further information is available at
www.iBioPharma.com.

Statements included in this release may constitute forward-looking statements
within the meaning of the Private Securities Litigation Reform Act of 1995. Such
statements involve a number of risks and uncertainties such as competitive
factors, technological development, market demand, and the company's ability to
obtain new contracts and accurately estimate net revenues due to variability in
size, scope and duration of projects, and internal issues in the sponsoring
client. Further information on potential risk factors that could affect the
company's financial results can be found in the company's Reports filed with the
Securities and Exchange Commission.